Compare · GLP-1 agonist
Mazdutide vs Tirzepatide
Both are glp-1 agonist compounds. Here's how they line up on the evidence — graded the same way.
| Mazdutide | Tirzepatide | |
|---|---|---|
| Evidence | Preliminary human | Strong human |
| Class | GLP-1 agonist | GLP-1 agonist |
| Summary | A GLP-1/glucagon dual agonist approved in China for weight loss and diabetes, with genuine RCT evidence that is still sponsor-funded and single-country. | A dual GIP/GLP-1 receptor agonist with strong RCT evidence for type 2 diabetes, weight loss, and sleep apnea; GI side effects are common. |
| Full profile → | Full profile → |
Mazdutide
Mazdutide is an injectable drug for weight loss and type 2 diabetes that activates two metabolic hormone receptors at once. Unlike most of the attention-grabbing GLP-1 compounds, it is not stuck at the press-release stage: it has a published Phase 3 trial in a major journal and is actually approved…
Tirzepatide
Tirzepatide is a once-weekly injectable peptide sold as Mounjaro (for type 2 diabetes) and Zepbound (for weight management and sleep apnea). Unlike most compounds we cover here, it has been tested in large, well-run human trials, and the results are unusually consistent. This is not medical advice.